Results 51 to 60 of about 2,835 (171)

Therapeutic interventions for PTSD – current evidence on the the role of psychedelics

European Psychiatry, 2021
Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychotherapy is the designated first line treatment for PTSD, although high rates of psychiatric and medical ...
I. Figueiredo, F. Viegas, F. Ferreira, A. Santos, J. Ramos, J. Miranda   +5 more
doaj   +1 more source

Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD

BMJ Open, 2023
Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition.
Alan K Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong, Rafaelle L Lancelotta   +4 more
doaj   +1 more source

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports, 2023
Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross, Robin L. Carhart-Harris   +7 more
doaj   +1 more source

Modalities for Psilocybin-Assisted Psychotherapy: A Review

, 2022
This paper will review the current literature on modalities used or proposed for psilocybin-assisted psychotherapy. Modalities have been offered for the treatment of depression, addiction, and the demoralisation of long term AIDS survivors.
Haworth, Nicole
core  

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source

Music Playlist Use in Clinical Trials of Psychedelic Assisted Psychotherapy: A Systematic Review

Journal of Clinical Psychology, EarlyView.
ABSTRACT Recent studies have shown promising results for psychedelics in the treatment of psychiatric disorders. Both in clinical and recreational settings, contextual elements, such as music, can influence the experience of users and may be linked to positive outcomes.
Lucas Cruz, Fernando R. Beserra, Julia M. K. Freind, Sandro E. Rodrigues, Daniel C. Mograbi   +4 more
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

The influence of psilocybin on subconscious and conscious emotional learning

iScience
Summary: Serotonergic psychedelics hold promise as a treatment modality for various psychiatric disorders and are currently applied in psychedelic-assisted psychotherapy.
Andrea F. Casanova, Andres Ort, John W. Smallridge, Katrin H. Preller, Erich Seifritz, Franz X. Vollenweider   +5 more
doaj   +1 more source

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression? [PDF]

Exploration of Neuroscience
Treatment resistant depression (TRD) is frequently encountered in clinical practice. The lack of response of the condition to conventional medications and augmentation strategies has spawned the search for novel treatment approaches.
Trevor R. Norman
doaj   +1 more source